Stock Scorer

Humacyte, Inc. (HUMA)

Humacyte, Inc. reported revenue of 406K USD for the quarter ending 30 June 2026, up 34.9% from 301K a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 406K +34.9%
Gross Profit Q2 '26 · ending 30 June 2026 -825K -1037.5%
Operating Income Q2 '26 · ending 30 June 2026 -27M —
Net Income Q2 '26 · ending 30 June 2026 -36.8M —
Cost of Revenue Q2 '26 · ending 30 June 2026 1.2M +477.9%
Operating Cash Flow Q2 '26 · ending 30 June 2026 -22.1M —
Free Cash Flow Q2 '26 · ending 30 June 2026 -22.2M —
Shares Outstanding Q2 '26 · ending 30 June 2026 234.2M +77.7%
EPS Q2 '26 · ending 30 June 2026 -0.55 —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 2M-108.1M-40.8M-105.9M
20242024-12-31 0-114.4M-148.7M-99.7M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-30406K
Q1 '262026-03-31495K
Q4 '252025-12-31467K
Q3 '252025-09-30753K
Q2 '252025-06-30301K
Q1 '252025-03-31517K
Q4 '242024-12-310
Q3 '242024-09-300
Q2 '242024-06-300
Q1 '242024-03-310
Q3 '212021-09-30241K
Q3 '202020-09-30914K

Gross Profit Quarterly

Revenue minus cost of sales. This filer tags no gross profit of its own..

PeriodEndingGross Profit
Q2 '262026-06-30-825K
Q1 '262026-03-31-1.5M
Q4 '252025-12-31-8.6M
Q3 '252025-09-30493K
Q2 '252025-06-3088K
Q1 '252025-03-31370K
Q4 '242024-12-310
Q3 '242024-09-300
Q2 '242024-06-300
Q1 '242024-03-310

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-27M
Q1 '262026-03-31-28.9M
Q4 '252025-12-31-30.8M
Q3 '252025-09-30-24.4M
Q2 '252025-06-30-29.7M
Q1 '252025-03-31-23.2M
Q4 '242024-12-31-28.1M
Q3 '242024-09-30-30.2M
Q2 '242024-06-30-29.5M
Q1 '242024-03-31-26.6M
Q4 '232023-12-31-26.2M
Q3 '232023-09-30-24.6M
Q2 '232023-06-30-26.7M
Q1 '232023-03-31-22.5M
Q4 '222022-12-31-20.8M
Q3 '222022-09-30-23.5M
Q2 '222022-06-30-18.5M
Q1 '222022-03-31-21.8M
Q4 '212021-12-31-21.6M
Q3 '212021-09-30-20.5M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-36.8M
Q1 '262026-03-31-17.6M
Q4 '252025-12-31-24.8M
Q3 '252025-09-30-17.5M
Q2 '252025-06-30-37.7M
Q1 '252025-03-3139.1M
Q4 '242024-12-31-20.9M
Q3 '242024-09-30-39.2M
Q2 '242024-06-30-56.7M
Q1 '242024-03-31-31.9M
Q4 '232023-12-31-25.1M
Q3 '232023-09-30-26M
Q2 '232023-06-30-22.7M
Q1 '232023-03-31-37M
Q4 '222022-12-31-3.7M
Q3 '222022-09-30-25.3M
Q2 '222022-06-3036.9M
Q1 '222022-03-31-19.8M
Q4 '212021-12-3142.6M
Q3 '212021-09-30-31.6M

Cost of Revenue Quarterly

PeriodEndingCost of Revenue
Q2 '262026-06-301.2M
Q1 '262026-03-312M
Q4 '252025-12-319.1M
Q3 '252025-09-30260K
Q2 '252025-06-30213K
Q1 '252025-03-31147K
Q4 '242024-12-310
Q3 '242024-09-300
Q2 '242024-06-300
Q1 '242024-03-310

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-22.1M
Q1 '262026-03-31-25.1M
Q4 '252025-12-31-26.1M
Q3 '252025-09-30-23.9M
Q2 '252025-06-30-26.4M
Q1 '252025-03-31-28.6M
Q4 '242024-12-31-26.6M
Q3 '242024-09-30-22.9M
Q2 '242024-06-30-21.3M
Q1 '242024-03-31-27.3M
Q4 '232023-12-31-19.1M
Q3 '232023-09-30-13M
Q2 '232023-06-30-22.6M
Q1 '232023-03-31-18.6M
Q4 '222022-12-31-19M
Q3 '222022-09-30-16.8M
Q2 '222022-06-30-16.6M
Q1 '222022-03-31-18.8M
Q4 '212021-12-31-21.4M
Q3 '212021-09-30-30.5M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30-22.2M
Q1 '262026-03-31-25.3M
Q4 '252025-12-31-26.2M
Q3 '252025-09-30-24M
Q2 '252025-06-30-27M
Q1 '252025-03-31-28.8M
Q4 '242024-12-31-26.6M
Q3 '242024-09-30-23.8M
Q2 '242024-06-30-21.5M
Q1 '242024-03-31-27.7M
Q4 '232023-12-31-19.2M
Q3 '232023-09-30-13.5M
Q2 '232023-06-30-23.1M
Q1 '232023-03-31-19.8M
Q4 '222022-12-31-19.6M
Q3 '222022-09-30-17M
Q2 '222022-06-30-16.7M
Q1 '222022-03-31-18.8M
Q4 '212021-12-31-21.5M
Q3 '212021-09-30-30.6M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30234.2M
Q1 '262026-03-31197.8M
Q3 '252025-09-30158.3M
Q2 '252025-06-30155.4M
Q1 '252025-03-31131.8M
Q3 '242024-09-30119.4M
Q2 '242024-06-30119.2M
Q1 '242024-03-31108.2M
Q3 '232023-09-30103.4M
Q2 '232023-06-30103.4M
Q1 '232023-03-31103.3M
Q3 '222022-09-30103M
Q2 '222022-06-30103.9M
Q1 '222022-03-31103M
Q3 '212021-09-3044M
Q2 '212021-06-305.9M
Q1 '212021-03-315.9M
Q3 '202020-09-305.8M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-0.55
Q1 '262026-03-31-0.63
Q4 '252025-12-31-0.26
Q3 '252025-09-30-0.23
Q2 '252025-06-30-0.45
Q1 '252025-03-31-0.69
Q4 '242024-12-31-1.26
Q3 '242024-09-30-1.34
Q2 '242024-06-30-1.26
Q1 '242024-03-31-1.00
Q4 '232023-12-31-1.07
Q3 '232023-09-30-0.86
Q2 '232023-06-30-0.86
Q1 '232023-03-31-0.29
Q4 '222022-12-31-0.12
Q3 '222022-09-306.32
Q2 '222022-06-305.85
Q1 '222022-03-312.61
Q4 '212021-12-31-0.66
Q3 '212021-09-30-9.87